Nationwide Children’s spinoff Lattice Biotech looking to raise $5M

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

A spinoff from research at Nationwide Children’s Hospital is seeking to raise $5 million to advance a therapy to weaken bacterial colonies in chronic infections so antibiotics or the immune system can attack them.

Lattice Biotech LLC was formed last year to license the hospital’s technology to create antibodies that break down proteins key to forming a biofilm – more colorfully described as “slime-enclosed aggregates” – shielding bacterial colonies in conditions including cystic fibrosis, severe ear infections and periodontal disease.

Click here to read the complete article.

Originally published March 30, 2015.